Mother and son jogging Mother and son jogging Mother and son jogging Mother and son jogging
Advanced Search
  • Feb 19, 2021
    Abbott Declares 389th Consecutive Quarterly Dividend
  • Feb 1, 2021
    Easterseals and the Abbott Fund Join Together to Advance Health Equity Through the Black Child Fund
    - Support for the Easterseals Black Child Fund Will Advance Early Identification and Interventions Among Black Children to Reduce Health Disparities Often Experienced in Early Childhood
  • Jan 27, 2021
    Abbott Reports Fourth-Quarter 2020 Results; Issues Strong Double-Digit Growth Forecast for 2021
    - Sales of $10.7 billion, including $2.4 billion of COVID-19 diagnostic testing-related sales
    - Sales growth of 28.7 percent; organic sales growth of 28.4 percent
    - GAAP diluted EPS from continuing operations growth of 103.4 percent; adjusted diluted EPS growth of 52.6 percent
    - Delivered more than 300 million COVID-19 diagnostics tests in fourth quarter 2020
    - R&D pipeline continues to be highly productive, delivering ground-breaking innovations and a steady cadence of important new products across all business areas
    - Issues 2021 EPS growth forecast of more than 35 percent
  • Jan 26, 2021
    Abbott's Panbio Rapid Antigen Test Receives CE Mark for Asymptomatic Screening and Self-Administered Sample Collection with Nasal Swab
    - Panbio™ COVID-19 Ag Rapid Test Device supports mass testing in congregate populations of people (mass screening) who are asymptomatic
    - Frequent screening of asymptomatic and symptomatic people helps restore a sense of safety at workplaces, schools, travel and recreational settings, and other places where people gather in large numbers
    - Test is approved for use with a patient-friendly and minimally invasive nasal swab; patients can self-administer sample collection under a healthcare professional's supervision
    - Panbio COVID-19 Ag delivers results in as early as 15 minutes with no instrumentation, using proven Abbott lateral flow technology
    - Test performance in clinical study demonstrated 93.8% sensitivity and 100.0% specificity in asymptomatic people with high viral loads
    - Along with the test, Abbott will offer complementary digital solutions: the NAVICA™ mobile app to allow people to display negative results for proof of testing and Sympheos™ for surveillance management to understand epidemiological trends
    - Since August 2020 to date, Abbott has shipped 200 million Panbio rapid antigen tests to 120 countries worldwide
  • Jan 20, 2021
    Abbott Receives Expanded Medicare Reimbursement for First-Of-Its-Kind MitraClip™ Device
    - New national reimbursement enables access to transcatheter mitral valve repair procedures with MitraClip for people with secondary mitral regurgitation, significantly expanding the eligible patient population
Show 5102550100 per page
true
accessibility

You are about to exit for another Abbott country or region specific website

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.


The website you have requested also may not be optimized for your specific screen size.

Do you wish to continue and exit this website?

yesno
accessibility

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?

yesno
accessibility

Asset Warning

yesno